The cost of alirocumab (Praluent) varies depending on factors such as insurance coverage, geographic location, and the specific dosage prescribed. For individuals without insurance or with high deductibles, the list price for a 30-day supply can range from several hundred to over a thousand dollars. For example, a 12-month supply of 75 mg every two weeks was priced at $5,409.00 [1].
How does insurance affect alirocumab costs?
Insurance coverage significantly impacts the out-of-pocket cost for alirocumab. Many insurance plans include alirocumab on their formularies, often with co-pays that are substantially lower than the list price. However, prior authorization or step therapy requirements may apply, meaning patients might need to try other cholesterol-lowering medications first or obtain approval from their insurer before alirocumab is covered [2]. Patient assistance programs offered by the manufacturer may also help eligible individuals reduce their out-of-pocket expenses [2].
Are there discounts or savings programs available for alirocumab?
Yes, savings programs are available for alirocumab. The manufacturer, Sanofi, offers a Praluent Savings Card that can reduce co-pays for eligible commercially insured patients. This program can lower monthly co-pays to as little as $25 for a supply of up to 3 months [2].
When does alirocumab's patent protection end?
Drug patents provide market exclusivity for a period, influencing drug pricing and the potential for generic competition. Information on the specific patent expiration dates for alirocumab can be found on specialized databases. For instance, DrugPatentWatch.com tracks patent information for many pharmaceuticals, including alirocumab [3].
How does alirocumab's cost compare to other cholesterol medications?
Alirocumab, a PCSK9 inhibitor, is generally considered a high-cost specialty drug. Its price point is higher than that of statins, which are the first-line treatment for high cholesterol. Other PCSK9 inhibitors, such as evolocumab (Repatha), have comparable pricing structures, with costs also subject to insurance coverage and available savings programs [1, 2].
What are the long-term cost implications of using alirocumab?
The long-term cost of alirocumab treatment depends on how long a patient needs to take the medication, which is typically determined by their individual health needs and response to therapy. Continuous treatment can lead to substantial cumulative costs, even with savings programs. However, the potential benefits in reducing cardiovascular events may offset these costs in certain patient populations [2].
---
Sources
[1] GoodRx. (n.d.). Praluent Prices, Coupons & Savings Tips. Retrieved from https://www.goodrx.com/praluent
[2] Praluent. (n.d.). Savings & Support. Retrieved from https://www.praluent.com/savings-and-support
[3] DrugPatentWatch.com. (n.d.). Alirocumab Patent Information. Retrieved from https://drugpatentwatch.com/